quote is from the automated transcript, cleaned for reading:
filler sounds and stutters are removed, nothing is rephrased. names can be misheard
(the analysis reads context, assessments check outside sources). how →
More from Oleg Noodleman
PredictionNot checkable as stated
Nodelman: Aktis Oncology could reach a $10B valuation if one program succeeds
“We think Actis could be worth ten billion or 200 dollars per share if even one of their programs makes it to market, and in this case, you have a lot of outs.”
Oleg NoodlemanJun 12, 2026▶ 34:33All-In's Best Ideas Pitch Competition: 4 Investors Present Their Top Trades Live
AssertionSupported
Nodelman: Aktis Oncology's IPO was 18x oversubscribed, backstopped by Eli Lilly
“Actis was started five years ago, but recently went public with a three hundred million dollar IPO that was 18 times oversubscribed, and backstopped with a hundred million dollar order by Eli Lilly, the folks who bring you all the weight loss drugs.”
Oleg NoodlemanJun 12, 2026▶ 31:38All-In's Best Ideas Pitch Competition: 4 Investors Present Their Top Trades Live
Made with StarZero
Turn any episode into a week of clips.
This entire site, over 460 episodes transcribed, diarized, checked and made playable,
runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the
moments worth sharing, cuts them, captions them, and reframes them for every feed.
We use essential cookies to make the site work. With your permission we
also use analytics cookies (Google Analytics and Mixpanel) to understand
usage and improve StarZero. See our Cookie Policy.